|Articles|April 16, 2021

Rates of Vaccinations in Children See Decline During COVID-19 Pandemic

Author(s)Killian Meara

The ongoing pandemic has caused a severe decrease in childhood vaccinations, while some rates have recovered, others have not and clinicians are urging caregivers to have their children receive their shots.

A recent study conducted by investigators from the Kaiser Permanente integrated managed care consortium has found that the numbers of recommended vaccine doses administered to children, like the measles vaccine, saw a sharp decrease when a national state of emergency was declared due to the COVID-19 pandemic.

Results from the study were published in the journal Pediatrics.

For the study, investigators analyzed the uptake and coverage for recommended vaccines at Kaiser Permanente in Southern California. Vaccine uptake is the number of children who are getting their vaccines, while vaccine coverage is the measure of the proportion of children who are vaccinated at a specific age.

The investigators looked at data from January through August of 2020, and compared it with the same period in 2019.

Findings from the study saw an overall decline in children being vaccinated during the pandemic, although it completely recovered in children under the age of 2 by May and somewhat recovered in older children.

Measles vaccinations saw an initial decline of up to 93% among children aged 2 to 18 years old. It slightly recovered but rates remained lower than in 2019. Additionally, measles vaccinations were unchanged in patients aged 7, but significantly decreased in patients aged 16 months and has only worsened over time.

"While the severe decrease in measles vaccine uptake among children improved, measles vaccine uptake remained substantially reduced, so the population of unvaccinated children is continuing to grow," Bradley Ackerson, the lead author on the study said. "The decrease in measles vaccine uptake is very concerning as even a 2% to 5% reduction in measles vaccination coverage is projected to result in exponential increases in measles outbreaks."

Clinicians at Kaiser Permanente are attempting to address this issue by contacting members whose children are due for their vaccinations and offering them reassurance about measures being taken to ensure a safe environment.

They have implemented measures including masking, social distancing, hygiene procedures and separating sick visits from well visits.

"This is a case where the benefit of vaccination far outweighs the risk of visiting a medical office,” Robert Riewerts, a co-author on the study said. “Our medical offices are taking every precaution to keep kids and their families safe."


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.